Dendreon Corp fka DNDNQ

[DewDiligence]

>Even in a PSB world that is below the raw (no Cox Correction) HR for 9902a (the *second* trial).<

Yes—1.25 is barely below the raw 9902a HR.

Taking into account PSB, the somewhat different patient pools of 9902b and earlier trials, the poorly understood MoA, the tepid measured immune response, and the failures of many other cancer immunotherapies, 1.25 seems about right. Of the above, PSB and the failures of many other cancer immunotherapies are the largest factors, IMO.

Those who look at only the prior Provenge trials to estimate the true underlying treatment effect in 9902b are exhibiting a severe form of myopia, IMHO. Regards, Dew

p.s. Ordinary myopia is treatable with LASIK, but this kind of myopia may not be treatable.